3,382 Shares in Danaher Corporation $DHR Bought by Teewinot Capital Advisers L.L.C.

Key Points

• Teewinot Capital Advisers L.L.C. has acquired a new position in Danaher Corporation, purchasing 3,382 shares valued at approximately $693,000 during the 1st quarter.
• Danaher Corporation reported a quarterly earnings per share (EPS) of $1.80, surpassing analysts' expectations and showing a 3.4% increase in revenue year-over-year.
• Insider Director Teri List sold 2,778 shares for $586,324, representing an 11.81% decrease in her ownership of the stock.

Teewinot Capital Advisers L.L.C. bought a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 3,382 shares of the conglomerate's stock, valued at approximately $693,000.

Several other large investors have also bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after acquiring an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the period. Bank of New York Mellon Corp raised its position in shares of Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after buying an additional 194,466 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Danaher by 11.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after buying an additional 579,046 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after buying an additional 1,450,703 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Down 2.2%

DHR traded down $4.39 during trading on Tuesday, hitting $194.24. 3,344,891 shares of the stock traded hands, compared to its average volume of 2,899,976. The firm has a market capitalization of $139.09 billion, a P/E ratio of 41.33, a price-to-earnings-growth ratio of 2.77 and a beta of 0.75. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The firm has a 50-day moving average of $201.82 and a 200 day moving average of $199.20. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter in the prior year, the company posted $1.72 EPS. The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. Danaher's dividend payout ratio is currently 27.23%.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 11.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have issued reports on DHR. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research report on Tuesday, September 2nd. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Evercore ISI dropped their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Robert W. Baird raised their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.